These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365 [TBL] [Abstract][Full Text] [Related]
13. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911 [TBL] [Abstract][Full Text] [Related]
14. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy. Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J Front Immunol; 2024; 15():1307558. PubMed ID: 38304433 [TBL] [Abstract][Full Text] [Related]
15. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066 [TBL] [Abstract][Full Text] [Related]
16. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study. Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients. Tsuboi K; Yamamoto H BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315 [TBL] [Abstract][Full Text] [Related]
18. Urinary mulberry bodies as a potential biomarker for early diagnosis and efficacy assessment of enzyme replacement therapy in Fabry nephropathy. Yonishi H; Namba-Hamano T; Hamano T; Hotta M; Nakamura J; Sakai S; Minami S; Yamamoto T; Takahashi A; Kobayashi W; Maeda I; Hidaka Y; Takabatake Y; Sakai N; Isaka Y Nephrol Dial Transplant; 2021 Dec; 37(1):53-62. PubMed ID: 33367839 [TBL] [Abstract][Full Text] [Related]
19. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease. Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518 [TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Schaefer RM; Tylki-Szymańska A; Hilz MJ Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]